Can SS-31 be prescribed?
Yes. Elamipretide, also known as SS-31, is the active ingredient in the prescription drug Forzinity. A compounded SS-31 prescription follows a separate pathway, with its own clinical and pharmacy requirements. Here is what that means if you are exploring mitochondrial health, energy or recovery.
Is SS-31 FDA-approved?
Elamipretide has an FDA-approved use: Forzinity is indicated to improve muscle strength in adults and children with Barth syndrome who weigh at least 30 kilograms. FDA granted accelerated approval in September 2025. That is a meaningful milestone for a peptide targeting the mitochondria, the energy-producing structures inside cells. The manufacturer must complete a confirmatory trial as part of that approval. Read the prescribing information.
The distinction for shoppers is specific: the approval applies to Forzinity for Barth syndrome. It does not establish SS-31 as a proven treatment for everyday fatigue, healthy aging or athletic recovery. A compounded preparation may use elamipretide as its active ingredient, but it is not the approved product and has not undergone FDA premarket review.
Can a pharmacy compound SS-31?
Compounding may be possible when the exact ingredient and preparation meet the applicable requirements. Under section 503A, being a component of an FDA-approved drug is one route by which a bulk ingredient may qualify, when no applicable USP or NF monograph exists. The pharmacy must also satisfy the other compounding conditions, including rules on preparations that are essentially copies of commercially available drugs. A prescription alone does not settle those questions. FDA explains ingredient eligibility and the rules for copies of commercial products.
For the patient, the next step is straightforward: discuss why a particular preparation is appropriate for your needs, and confirm that the dispensing pharmacy can supply it under the applicable requirements. Availability depends on the formulation, pharmacy and state.
What does the research say about energy and fatigue?
SS-31 has been studied in people with mitochondrial diseases, so there is human research to discuss. In the 218-person MMPOWER-3 trial, elamipretide did not demonstrate improvement on the primary walking-distance or fatigue outcomes compared with placebo over 24 weeks. That finding applies to the studied population with primary mitochondrial myopathy; it does not establish a benefit for healthy adults seeking more energy. Read the trial results.
Researchers have also examined whether genetic differences help explain who responds. A later, exploratory post hoc analysis of the same trial examined signals in specific subgroups to inform further trials. That is a reason for continued investigation, rather than a confirmed way to select a treatment for general fatigue. Read the follow-up analysis.
What should you discuss with your clinician?
Start with the change you want to make: better stamina, less fatigue or a more reliable return to activity. Your history, medications and symptoms help a clinician decide what to investigate and which options fit. Persistent fatigue can have several causes; identifying yours makes the conversation more useful than starting with a compound alone.
Bring three questions: What evidence applies to my situation? Why this preparation rather than another option? How would we judge whether the plan is helping? Also discuss adverse effects and monitoring. The approved elamipretide label includes injection-site reactions and serious hypersensitivity reactions; an individual plan needs its own safety review.
What does AnthologyRX bring to peptide care?
Your assessment is reviewed by an independent licensed clinician, and prescriptions are dispensed through licensed US pharmacies. We have verified our compounding partners’ quality programs, including identity and potency testing, batch documentation, independent testing and sterile-product controls for injectables. These are concrete safeguards around preparation and dispensing. Our guide to research-grade and pharmacy-compounded peptides explains what each quality check tells you.
How do you explore SS-31 through AnthologyRX?
Our SS-31 page brings the listed format, plan details and assessment pathway together. Independent licensed clinicians review your health information and determine whether treatment is appropriate. You can also compare SS-31 with MOTS-c before deciding what to ask about.
Sources
- Forzinity (elamipretide) prescribing information
DailyMed. Accelerated approval, September 2025, to improve muscle strength in patients with Barth syndrome weighing at least 30 kg.
- Karaa et al. MMPOWER-3 elamipretide trial
Neurology, 2023. Primary mitochondrial myopathy; primary walking and fatigue outcomes not met.
- Karaa et al. Genotype-specific MMPOWER-3 follow-up analysis
Orphanet Journal of Rare Diseases, 2024. Exploratory genotype analyses to inform additional research, not established benefits for healthy adults.
- FDA: Bulk drug substances used in compounding under section 503A
Ingredient requirements, the final 503A bulks list and the separate interim policy for nominated substances. A prescription alone does not establish ingredient eligibility.
- FDA: Compounded products that are essentially copies of commercially available drugs
Section 503A guidance on commercially available products, essentially copies and patient-specific differences.
- FDA: Compounding questions and answers
What compounded drugs are, how 503A pharmacies and 503B outsourcing facilities differ, and why compounded drugs are not FDA-approved.
